BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36452965)

  • 21. Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?
    Hu Y; Fu K; Liu H; He Q; Qiu X; Yang W; Zhang Y
    J Ovarian Res; 2023 Jan; 16(1):18. PubMed ID: 36670456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic performance of MR imaging findings and quantitative values in the differentiation of seromucinous borderline tumour from endometriosis-related malignant ovarian tumour.
    Kurata Y; Kido A; Moribata Y; Kameyama K; Himoto Y; Minamiguchi S; Konishi I; Togashi K
    Eur Radiol; 2017 Apr; 27(4):1695-1703. PubMed ID: 27553934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors.
    Yasunaga M; Ohishi Y; Oda Y; Misumi M; Iwasa A; Kurihara S; Nishimura I; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
    Hum Pathol; 2009 Jul; 40(7):965-74. PubMed ID: 19269675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
    N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinicopathologic study of seromucinous carcinoma of ovary].
    Tang SX; Sun YH; Xu Y; Zhou XR; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2016 Nov; 45(11):774-779. PubMed ID: 27821232
    [No Abstract]   [Full Text] [Related]  

  • 26. Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis.
    Lee KR; Nucci MR
    Int J Gynecol Pathol; 2003 Jan; 22(1):42-51. PubMed ID: 12496697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms.
    Maeda D; Shih IeM
    Adv Anat Pathol; 2013 Jan; 20(1):45-52. PubMed ID: 23232571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MR findings for differentiating decidualized endometriomas from seromucinous borderline tumors of the ovary.
    Ando T; Kato H; Kawaguchi M; Furui T; Morishige KI; Hyodo F; Matsuo M
    Abdom Radiol (NY); 2020 Jun; 45(6):1783-1789. PubMed ID: 31960119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anaplastic carcinoma in ovarian seromucinous cystic tumor of borderline malignancy.
    Okumura T; Muronosono E; Tsubuku M; Terao Y; Takeda S; Maruyama M
    J Ovarian Res; 2018 Sep; 11(1):77. PubMed ID: 30176911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
    Barreta A; Sarian LO; Ferracini AC; Costa LBE; Mazzola PG; de Angelo Andrade L; Derchain S
    Hum Pathol; 2019 Mar; 85():72-81. PubMed ID: 30447298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytological Appearances of Ovarian Seromucinous Borderline Tumor in Ascites: Presentation of 2 Cases.
    Kai K; Hashiguchi M; Kurihara M; Tanaka Y; Kitamura S; Nakamura M; Shichijo C; Yamamoto-Rikitake M; Okuma R; Hikari T; Okuma E; Uchiyama M; Aoki S; Nakao Y; Yokoyama M; Aishima S
    Acta Cytol; 2021; 65(5):440-447. PubMed ID: 34284376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Endometriosis-related ovarian tumors].
    Schmidt D; Ulrich U
    Pathologe; 2014 Jul; 35(4):348-54. PubMed ID: 24992974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
    Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
    Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases.
    Vang R; Gown AM; Barry TS; Wheeler DT; Ronnett BM
    Mod Pathol; 2006 Jan; 19(1):97-105. PubMed ID: 16294196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor.
    Zhao C; Bratthauer GL; Barner R; Vang R
    Am J Surg Pathol; 2007 Sep; 31(9):1378-86. PubMed ID: 17721194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Case of Stage 4B Seromucinous Ovarian Borderline Tumor With Endometriosis and Review of the Literature.
    Newton CL; Brockbank E; Singh N; Faruqi A
    Int J Gynecol Pathol; 2017 Mar; 36(2):195-199. PubMed ID: 27362901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
    Guan B; Mao TL; Panuganti PK; Kuhn E; Kurman RJ; Maeda D; Chen E; Jeng YM; Wang TL; Shih IeM
    Am J Surg Pathol; 2011 May; 35(5):625-32. PubMed ID: 21412130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seromucinous borderline tumor of the testis-A case report.
    Scholz B; Beckert M; Mordstein V; Hohmann N; Walther R; Papadopoulos T
    Hum Pathol; 2017 Feb; 60():188-191. PubMed ID: 27597522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
    Groisman GM; Meir A; Sabo E
    Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
    Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
    Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.